Recruiting more women into clinical trials can transform cardiac care, according to a new study. Researchers found that greater female participation in heart device research not only uncovered critical sex-based differences but also improved understanding of how treatments work for all patients. Findings were published Aug. 25 in eClinicalMedicine.
Focusing on Non-Ischemic Cardiomyopathy
The trial centered on patients with non-ischemic cardiomyopathy, a weakening of the heart muscle unrelated to blocked arteries. This condition disproportionately affects women, yet prior studies often focused on ischemic cardiomyopathy, which is more common in men.
As a result, women historically were underrepresented in earlier research on implantable cardiac defibrillators (ICDs).
What ICDs Do
ICDs are small implants that monitor heart rhythms. If a dangerous arrhythmia occurs, the device delivers an electric shock to restore normal rhythm or restart the heart during cardiac arrest. These devices have been life-saving for many patients with weakened heart muscles or irregular heartbeats.
Landmark Participation of Women
In the new study, researchers intentionally prioritized female enrollment. Out of 1,000 participants with non-ischemic cardiomyopathy, nearly 48% were women. This far exceeded the 15% to 29% participation rates in past ICD trials, creating one of the most balanced cardiac device studies to date.
Key Findings on Risk Differences
Results revealed a striking difference between sexes. Men with non-ischemic cardiomyopathy were twice as likely as women to die or suffer life-threatening heart rhythm problems when treated with ICDs. Within a year of implantation, about 13% of men experienced severe arrhythmias, compared with just 6% of women.
Expert Insight from Researchers
“This is the first study with enough female participants to demonstrate this difference,” said lead investigator Dr. Valentina Kutyifa, professor of cardiology research at the University of Rochester Medical Center. She emphasized that while both men and women benefit from ICDs, females carry a lower residual risk of dangerous complications.
Implications for Patient Care
According to Kutyifa, these results could guide more personalized treatments. Doctors may use this data to better identify high-risk patients and adjust treatment intensity. Recognizing gender-specific differences in cardiac outcomes allows clinicians to refine care strategies, ultimately improving safety and survival rates for all patients.
Overcoming Barriers to Participation
Achieving strong female enrollment required tackling long-standing barriers. Women often face competing demands from caregiving responsibilities, lack of study awareness, or assumptions by doctors that they are ineligible. To address this, researchers coordinated study visits with regular medical appointments and expanded remote monitoring options to ease time burdens.
Surpassing Enrollment Goals
Initially, researchers aimed for 40% female participation. By redesigning trial logistics around patient needs, they surpassed expectations with women making up almost half of all participants. This shift provided more reliable data that better reflects the real-world population, offering a clearer picture of how treatments affect both sexes.
Broader Lessons for Clinical Research
The study demonstrates how inclusivity in clinical research benefits everyone. By ensuring diverse representation, researchers can identify differences in treatment outcomes that would otherwise remain hidden. In this case, men’s higher residual risk might not have been recognized without a strong baseline of female participants.
Ongoing Follow-Up
The trial will continue tracking participants for at least three years. Researchers expect further insights as longer-term data accumulates. The ongoing results may influence updated guidelines for ICD use, particularly for non-ischemic cardiomyopathy patients, and strengthen the case for equitable recruitment practices across all medical research.
Moving Toward Equity in Medicine
“As we’ve shown in this study, enrolling participants that better reflect the actual patient population benefits everyone, not just those historically excluded,” Kutyifa said. Ensuring equitable representation in clinical trials may be one of the most effective ways to advance both science and patient care.
